Eli Lilly And Co (NYSE:LLY) insider Donald A. Zakrowski sold 600 shares of the business’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $105.57, for a total transaction of $63,342.00. Following the completion of the sale, the insider now directly owns 3,530 shares in the company, valued at approximately $372,662.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

LLY traded down $1.03 during trading on Tuesday, reaching $104.62. 3,106,900 shares of the stock were exchanged, compared to its average volume of 4,169,074. The company has a market cap of $113.47 billion, a price-to-earnings ratio of 24.45, a PEG ratio of 1.76 and a beta of 0.27. Eli Lilly And Co has a twelve month low of $73.69 and a twelve month high of $106.49. The company has a current ratio of 1.40, a quick ratio of 1.09 and a debt-to-equity ratio of 0.79.

Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Tuesday, July 24th. The company reported $1.50 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.30 by $0.20. The business had revenue of $6.36 billion for the quarter, compared to the consensus estimate of $6.05 billion. Eli Lilly And Co had a negative net margin of 0.60% and a positive return on equity of 39.84%. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the previous year, the company earned $1.11 earnings per share. research analysts forecast that Eli Lilly And Co will post 5.47 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Monday, September 10th. Investors of record on Wednesday, August 15th will be issued a dividend of $0.5625 per share. The ex-dividend date is Tuesday, August 14th. This represents a $2.25 dividend on an annualized basis and a yield of 2.15%. Eli Lilly And Co’s payout ratio is 52.57%.

A number of institutional investors and hedge funds have recently modified their holdings of LLY. Integrated Wealth Concepts LLC acquired a new position in Eli Lilly And Co during the second quarter worth $103,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new position in shares of Eli Lilly And Co in the second quarter valued at $114,000. Legacy Advisors LLC increased its holdings in shares of Eli Lilly And Co by 118.0% in the second quarter. Legacy Advisors LLC now owns 1,354 shares of the company’s stock valued at $116,000 after purchasing an additional 733 shares during the last quarter. Fort L.P. acquired a new position in shares of Eli Lilly And Co in the second quarter valued at $121,000. Finally, Financial Management Professionals Inc. acquired a new position in shares of Eli Lilly And Co in the second quarter valued at $128,000. Institutional investors and hedge funds own 76.55% of the company’s stock.

LLY has been the topic of a number of research reports. BMO Capital Markets reissued a “hold” rating and issued a $78.00 price objective on shares of Eli Lilly And Co in a research report on Thursday, May 10th. Credit Suisse Group set a $82.00 price objective on shares of Eli Lilly And Co and gave the stock a “hold” rating in a research report on Tuesday, May 15th. Barclays set a $98.00 price objective on shares of Eli Lilly And Co and gave the stock a “buy” rating in a research report on Tuesday, May 22nd. Zacks Investment Research lowered shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Wednesday, May 23rd. Finally, ValuEngine raised shares of Eli Lilly And Co from a “sell” rating to a “hold” rating in a research report on Wednesday, May 23rd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the stock. Eli Lilly And Co presently has an average rating of “Buy” and an average target price of $100.13.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: Market Capitalization and Individual Investors

Insider Buying and Selling by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.